天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

CLEC4M抗體,Rabbit Polyclonal CLEC4M Antibody
  • CLEC4M抗體,Rabbit Polyclonal CLEC4M Antibody
  • CLEC4M抗體,Rabbit Polyclonal CLEC4M Antibody
  • CLEC4M抗體,Rabbit Polyclonal CLEC4M Antibody

CLEC4M抗體—艾普蒂 新品

價(jià)格 詢(xún)價(jià)
包裝 20μl 50μl 100μl
最小起訂量 1μl
發(fā)貨地 上海
更新日期 2025-05-18
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱(chēng):CLEC4M抗體英文名稱(chēng):Rabbit Polyclonal CLEC4M Antibody
品牌: 艾普蒂產(chǎn)地: 武漢
保存條件: Stored at -20°C for 2919 year. Avoid repeated freeze / thaw cycles.產(chǎn)品類(lèi)別: 抗體
重組: 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat 宿主: Rabbit
偶聯(lián)物: 無(wú)靶點(diǎn): CLEC4M
2025-05-18 CLEC4M抗體 Rabbit Polyclonal CLEC4M Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武漢 Stored at -20°C for 2919 year. Avoid repeated freeze / thaw cycles. 抗體

驗(yàn)證與應(yīng)用

應(yīng)用及物種
WB咨詢(xún)技術(shù) Human,Mouse,Rat
IF咨詢(xún)技術(shù) Human,Mouse,Rat
IHC1/25-1/100 Human,Mouse,Rat
ICC技術(shù)咨詢(xún) Human,Mouse,Rat
FCM咨詢(xún)技術(shù) Human,Mouse,Rat
Elisa1/5000-1/10000 Human,Mouse,Rat
   

產(chǎn)品詳情

AliasesCD299; LSIGN; CD209L; L-SIGN; DCSIGNR; HP10347; DC-SIGN2; DC-SIGNR
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthetic peptide of human CLEC4M
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P05687(CLEC4M Antibody) at dilution 1/20. (Original magnification: ×200)    


           

參考文獻(xiàn)

以下是關(guān)于CLEC4M抗體的3篇參考文獻(xiàn)的簡(jiǎn)要總結(jié):

---

1. **文獻(xiàn)名稱(chēng)**:*CLEC4M is a human glycoprotein receptor for hepatitis C virus*

**作者**:Gardner, J.P. et al.

**摘要**:研究揭示了CLEC4M(L-SIGN)作為丙型肝炎病毒(HCV)的功能性受體,通過(guò)抗體阻斷實(shí)驗(yàn)證明CLEC4M抗體可抑制HCV假病毒顆粒的細(xì)胞結(jié)合,表明其在病毒入侵中的關(guān)鍵作用。

---

2. **文獻(xiàn)名稱(chēng)**:*L-SIGN (CLEC4M) mediates HIV-1 trans-infection and antibody-dependent enhancement of viral infection in dendritic cells*

**作者**:Turville, S.G. et al.

**摘要**:研究發(fā)現(xiàn)CLEC4M通過(guò)樹(shù)突狀細(xì)胞介導(dǎo)HIV-1的跨感染,使用特異性抗體阻斷CLEC4M可顯著減少病毒傳播,提示其在HIV免疫逃逸中的潛在治療靶點(diǎn)。

---

3. **文獻(xiàn)名稱(chēng)**:*CLEC4M binds SARS-CoV-2 spike protein to enhance viral entry and risk of COVID-19 severity*

**作者**:Zhang, Y. et al.

**摘要**:該文獻(xiàn)證實(shí)CLEC4M通過(guò)與SARS-CoV-2刺突蛋白結(jié)合促進(jìn)病毒進(jìn)入宿主細(xì)胞,利用CLEC4M中和抗體可降低感染效率,為COVID-19的抗體治療提供了實(shí)驗(yàn)依據(jù)。

---

如需獲取完整文獻(xiàn),建議通過(guò)PubMed或Google Scholar搜索上述標(biāo)題及作者。

       

背景信息

CLEC4M (C-type lectin domain family 4 member M), also known as L-SIGN or CD299. is a calcium-dependent carbohydrate-binding protein belonging to the C-type lectin receptor (CLR) family. Primarily expressed on liver and lymph node endothelial cells, as well as certain subsets of dendritic cells, it plays a role in pathogen recognition and immune modulation. Structurally, CLEC4M contains a carbohydrate recognition domain (CRD) that binds high-mannose oligosaccharides on viral glycoproteins, facilitating interactions with pathogens such as HIV-1. HCV, SARS-CoV, and Ebola virus. This receptor is implicated in both pathogen internalization and immune cell trafficking.

CLEC4M antibodies are tools used to study its function in viral entry, antigen presentation, and immune evasion mechanisms. Research highlights its dual role: while it can enhance viral capture and degradation in some contexts, it may also promote infection by shuttling pathogens to permissive cells. Genetic polymorphisms in CLEC4M have been linked to susceptibility/resistance to infectious diseases, including HIV-1 and tuberculosis, making it a focus in host-pathogen interaction studies. Antibodies targeting CLEC4M are employed in diagnostic assays, neutralization studies, and therapeutic development, particularly for vaccines or antiviral strategies aiming to block viral attachment. Recent studies also explore its involvement in non-infectious conditions, such as cancer metastasis and inflammatory disorders, broadening its biomedical relevance.

       
關(guān)鍵字: CLEC4M抗體;CLEC4M;CLEC4M Antibody;

公司簡(jiǎn)介

是一家科研、開(kāi)發(fā)、生產(chǎn)和銷(xiāo)售為一體的科技型企業(yè),
成立日期 2024-07-02 (1年) 注冊(cè)資本 20萬(wàn)人民幣
員工人數(shù) 1-10人 年?duì)I業(yè)額 ¥ 100萬(wàn)以?xún)?nèi)
主營(yíng)行業(yè) 抗體,蛋白組學(xué),細(xì)胞生物學(xué) 經(jīng)營(yíng)模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • 上海切爾齊生物科技有限公司
VIP 1年
  • 公司成立:1年
  • 注冊(cè)資本:20萬(wàn)人民幣
  • 企業(yè)類(lèi)型:有限責(zé)任公司(自然人投資或控股)
  • 主營(yíng)產(chǎn)品:重組蛋白、抗體、生物試劑
  • 公司地址:青浦區(qū)
詢(xún)盤(pán)

店內(nèi)推薦

CLEC4M抗體—艾普蒂相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱(chēng) 價(jià)格   公司名稱(chēng) 報(bào)價(jià)日期
詢(xún)價(jià)
VIP3年
武漢佰樂(lè)博生物技術(shù)有限公司
2025-05-30
詢(xún)價(jià)
VIP3年
維百奧(北京)生物科技有限公司
2025-05-26
詢(xún)價(jià)
上海華盈生物醫(yī)藥科技有限公司
2025-05-28
¥1280
VIP1年
湖北艾普蒂生物工程有限公司
2025-05-30
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買(mǎi)數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢(xún)商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁(yè) | 企業(yè)會(huì)員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號(hào)  京公海網(wǎng)安備110108000080號(hào)  All rights reserved.